

**Brilliant Violet 605™ anti-human CD62L**

**Catalog # / Size:** 2124165 / 25 tests  
2124170 / 100 tests

**Clone:** DREG-56

**Isotype:** Mouse IgG1, κ


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** V S056

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD62L (clone DREG-56) Brilliant Violet 605™ (filled histogram) or mouse IgG1 Brilliant Violet 605™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for the relevant formats) include: Western blotting<sup>2,3,9</sup> and *in vitro* blocking of lymphocytes binding to high endothelial venules (HEV)<sup>2</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 304812).

**Application References:**

- Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Kishimoto TK, *et al.* 1990. *Proc. Natl. Acad. Sci. USA* 87:2244. (WB, Block)
- Jutila M, *et al.* 2002. *J. Immunol.* 169:1768. (WB)
- Tamassia N, *et al.* 2008. *J. Immunol.* 181:6563. (FC) [PubMed](#)

5. Kmiecik M, *et al.* 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
  6. Thakral D, *et al.* 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
  7. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  8. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
  9. Koenig JM, *et al.* 1996. *Pediatr. Res.* 39:616. (WB)
  10. Shi C, *et al.* 2011. *J. Immunol.* 187:5293. (FC) [PubMed](#)
  11. Burges M, *et al.* 2013. *Clin Cancer Res.* 19:5675. [PubMed](#)
  12. Cash JL, *et al.* 2013. *EMBO Rep.* 14:999. (FC) [PubMed](#)
- 

**Description:** CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycamin-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

**Antigen**  
**References:**

1. Kishimoto T, *et al.* 1990. *P. Natl. Acad. Sci. USA* 87:2244.
2. Kishimoto T, *et al.* 1991. *Blood* 78:805.